An interventional study of 6% hydroxyethyl starch 130/0.4 and 5% albumin in Mitral Valvular Heart Disease, sponsored by Yonsei University. Completed. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Yonsei University · Not applicable, Interventional, and Treatment
Comparison of 6% hydroxyethyl starch 130/0.4 with 5% albumin as priming solution for cardiopulmonary bypass
3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's enrollment of 36 is below the median of 100 across 1,778 interventional studies indexed under Heart Diseases.
Browse Heart Diseases studies →Yonsei University is the lead sponsor of 1,387 studies on the registry; 232 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: 6% hydroxyethyl starch 130/0.4 and 5% albumin
Drug: 6% hydroxyethyl starch 130/0.4 and 5% albumin
Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
the pure effect of priming solutions
Time frame: after CPB
No study locations are listed for this record.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yonsei University